{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06099418",
            "orgStudyIdInfo": {
                "id": "VB-C-04"
            },
            "secondaryIdInfos": [
                {
                    "id": "GOG-3091",
                    "type": "OTHER",
                    "domain": "GOG Foundation"
                }
            ],
            "organization": {
                "fullName": "Nykode Therapeutics ASA",
                "class": "INDUSTRY"
            },
            "briefTitle": "Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.",
            "officialTitle": "A Two-Arm Randomized, Double-Blind, Placebo-Controlled Phase 2 Selection Trial to Evaluate the Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With HPV16-Positive, PD-L1-positive, Recurrent or Metastatic Cervical Cancer Who Are Refractory to Pembrolizumab With Chemotherapy With/Without Bevacizumab.",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "efficacy-and-safety-of-alone-or-in-combination-with-atezolizumab-in-patients-with-advanced-cervical-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-18",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-10-19",
            "studyFirstSubmitQcDate": "2023-10-24",
            "studyFirstPostDateStruct": {
                "date": "2023-10-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Nykode Therapeutics ASA",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Roche Pharma AG",
                    "class": "INDUSTRY"
                },
                {
                    "name": "GOG Foundation",
                    "class": "NETWORK"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a multi-center study in patients with recurrent or metastatic HPV16-positive, PD-L1 positive cervical cancer who has progressed during or after treatment with the first-line standard of care (pembrolizumab with chemotherapy with/without bevacizumab).\n\nThe trial is designed to investigate VB10.16 alone or in combination with the immune checkpoint inhibitor, atezolizumab.\n\nThe trial consist of 2 parts: the first part which investigates VB10.16 + placebo versus VB10.16 + atezolizumab. Approximately 30 patients will be included in each group. The goal of this part is to evaluate which of the two treatments is the best.\n\nThe second part of the study will select the best treatment from part 1 and investigate the safety and efficacy of additional 70 patients.",
            "detailedDescription": "This is a two-arm randomized, double-blind, placebo-controlled phase 2 selection trial to evaluate the efficacy and safety of VB10.16 alone or in combination with atezolizumab in patients with HPV16-positive, PD-L1-positive, recurrent or metastatic cervical cancer who are refractory to pembrolizumab with chemotherapy with/without bevacizumab. A selection design with a margin of practical equivalence will be implemented to monitor efficacy of the two experimental arms (VB10.16 + atezolizumab vs. VB10.16 + placebo).\n\nThe trial consist of 2 parts: the first part which investigates VB10.16 + placebo versus VB10.16 + atezolizumab. Approximately 30 patients will be included in each group. The goal of this part is to evaluate which of the two treatments is the superior.\n\nThe second part of the study will select the superior treatment from part 1 and investigate the safety and efficacy of additional 70 patients."
        },
        "conditionsModule": {
            "conditions": [
                "HPV-Related Cervical Carcinoma",
                "HPV-Related Malignancy",
                "Cervical Cancer"
            ],
            "keywords": [
                "Recurrent",
                "metastatic",
                "HPV16-positive",
                "PD-L1 positive"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "A modified randomized phase 2 selection ('pick-the-winner') design with a margin of practical equivalence will be implemented to monitor efficacy of the two individual arms, and to decide which of the two arms that may be continued further based on the primary endpoint of confirmed ORR.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 130,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "VB10.16 + placebo",
                    "type": "EXPERIMENTAL",
                    "description": "9 mg VB10.16 via i.m. needle free injections in the deltoid muscles and quadricep or gluteus muscle.\n\nPlacebo will be given via IV infusions.",
                    "interventionNames": [
                        "Biological: VB10.16",
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "VB10.16 + atezolizumab",
                    "type": "EXPERIMENTAL",
                    "description": "9 mg VB10.16 via i.m. needle free injections in the deltoid muscles and quadricep or gluteus muscle.\n\nAtezolizumab will be given via IV infusions.",
                    "interventionNames": [
                        "Biological: VB10.16",
                        "Drug: Atezolizumab Injection [Tecentriq]"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "VB10.16",
                    "description": "Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 49.\n\nA total of up to 11 i.m. administrations will be given. VB10.16 will be administered via Pharma Jet\u00ae Stratis 0.5 mL needle free injection system.",
                    "armGroupLabels": [
                        "VB10.16 + atezolizumab",
                        "VB10.16 + placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Atezolizumab Injection [Tecentriq]",
                    "description": "Intravenous (IV) infusions of atezolizumab (saline solution) every 3 weeks.",
                    "armGroupLabels": [
                        "VB10.16 + atezolizumab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Intravenous (IV) infusions of placebo (saline solution) every 3 weeks.",
                    "armGroupLabels": [
                        "VB10.16 + placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Objective Response Rate (ORR)",
                    "description": "Objective Response Rate (ORR), defined as the proportion of patients who have either confirmed CR or confirmed PR as best overall response per RECIST 1.1 as assessed by blinded independent central review (BICR).",
                    "timeFrame": "Up to 1 year"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Objective Response Rate (ORR)",
                    "description": "Objective Response Rate (ORR), defined as the proportion of patients who have either confirmed CR or confirmed PR as best overall response per RECIST 1.1 as assessed by the investigator.",
                    "timeFrame": "Up to approximately 2 year"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "Duration of response (DOR) based upon RECIST v1.1 assessed by BICR. DOR is defined as time from the date of first documented response of confirmed CR or PR to the date of the first documented progression or death due to any cause, whichever occur first.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "Duration of response (DOR) based upon RECIST v1.1 assessed by the investigator. DOR is defined as time from the date of first documented response of confirmed CR or PR to the date of the first documented progression or death due to any cause, whichever occur first.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Time to Response (TTR)",
                    "description": "Time to response (TTR) based upon RECIST v1.1 assessed by BICR. TTR is defined as the time from VB10.16 treatment start date to the date of first documented response of either confirmed CR or confirmed PR.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Disease Control Rate (DCR)",
                    "description": "Disease Control Rate (DCR) based upon RECIST v1.1 assessed by BICR. DCR is defined as the proportion of patients who have either confirmed CR, confirmed PR, or SD as best overall response.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Duration of Disease Control (DODC)",
                    "description": "Duration of disease control (DODC) based upon RECIST v1.1 assessed by BICR. DODC is defined as time from the date of first documented response of confirmed CR, confirmed PR or SD to the date of the first documented progression or death due to any cause.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Progression Free Survival (PFS)",
                    "description": "Progression-free survival (PFS) as assessed by BICR. PFS is defined as the time from the VB10.16 treatment start date to the date of the first documented progression or death from any cause, whichever occurs first.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Progression Free Survival (PFS)",
                    "description": "Progression-free survival (PFS) as assessed by the investigator. PFS is defined as the time from the VB10.16 treatment start date to the date of the first documented progression or death from any cause, whichever occurs first.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Overall survival (OS)",
                    "description": "Overall survival (OS), defined as the time from VB10.16 treatment start date to the date of death from any cause.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Minimal Response",
                    "description": "Proportion of participants with tumor shrinkage \u226510.0% to \\<30% assessed by BICR.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Proportion of participants who are Progression-free",
                    "description": "Proportion of participants who are progression-free and alive based upon RECIST v1.1 assessed by BICR.",
                    "timeFrame": "26 weeks"
                },
                {
                    "measure": "Proportion of participants who are Progression-free",
                    "description": "Proportion of participants who are progression-free and alive based upon RECIST v1.1 assessed by BICR.",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "Proportion of participants who are Progression-free",
                    "description": "Proportion of participants who are progression-free and alive based upon RECIST v1.1 assessed by BICR.",
                    "timeFrame": "104 weeks"
                },
                {
                    "measure": "Proportion of participants who are alive.",
                    "description": "Proportion of participants who are alive.",
                    "timeFrame": "26 weeks"
                },
                {
                    "measure": "Proportion of participants who are alive.",
                    "description": "Proportion of participants who are alive.",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "Proportion of participants who are alive.",
                    "description": "Proportion of participants who are alive.",
                    "timeFrame": "104 weeks"
                },
                {
                    "measure": "Molecular Response",
                    "description": "Proportion of participants with molecular response defined as \u226530% decrease from baseline in HPV16 ctDNA.",
                    "timeFrame": "Up to week 52"
                },
                {
                    "measure": "Molecular Response",
                    "description": "Proportion of participants with molecular response defined as \u226550% decrease from baseline in HPV16 ctDNA.",
                    "timeFrame": "Up to week 52"
                },
                {
                    "measure": "Proportion of participants with treatment emergent adverse events",
                    "description": "Proportion of participants with treatment-emergent adverse events (TEAEs) by severity grade.",
                    "timeFrame": "Up to week 104"
                },
                {
                    "measure": "Proportion of participants with treatment-emergent serious adverse events",
                    "description": "Proportion of participants with treatment-emergent serious adverse events",
                    "timeFrame": "Up to week 104"
                },
                {
                    "measure": "Proportion of participants with drug related toxicity",
                    "description": "Proportion of participants with drug-related toxicity of CTCAE grade \u22653",
                    "timeFrame": "Up to week 104"
                },
                {
                    "measure": "Proportion of participants with discontinuation",
                    "description": "Proportion of participants discontinuing treatment due to an adverse reaction.",
                    "timeFrame": "Up to week 104"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Age \u226518 years at ICF signature date.\n2. Persistent recurrent or metastatic (R/M) (stage IVB) PD-L1 positive cervical cancer with squamous cell, adenocarcinoma or adenosquamous histology with confirmed disease progression during or after treatment with 1st line systemic standard of care pembrolizumab + platinum-containing chemotherapy +/- bevacizumab\n\n   1. Participants should have received at least 4 cycles of pembrolizumab.\n   2. Planned treatment start should be within 12 weeks of documented radiographic disease progression.\n   3. Participants should have received no more than 1 prior systemic anti-cancer treatment regimen for recurrent/metastatic cervical cancer (pembrolizumab + chemotherapy +/- bevacizumab).\n3. PD-L1-positive tumor confirmed by Ventana SP263 clone (the Food and Drug Administration approved companion diagnostic test for atezolizumab in other indications), with tumor area positivity \u22655% in designated central laboratory\n4. HPV16-positive tumor confirmed by nucleic acid amplification test in designated central laboratory\n5. At least 1 measurable lesion per RECIST v1.1 as assessed by Blinded Independent Central Review.\n\n   Overall function and organ function:\n6. ECOG performance status (PS) \u22641\n7. Gustave Roussy Immune (GRIm) score \u22641\n\nKey Exclusion Criteria:\n\nDisease specific:\n\n1. Has disease that is suitable for local therapy with curative intent.\n2. Rapidly progressing disease (e.g., tumor bleeding, uncontrolled tumor pain) in the opinion of the investigator.\n3. Neuroendocrine carcinoma of the cervix.\n\n   Prior, concurrent or future interventions:\n4. Radiotherapy (or other non-systemic therapy) \u226414 days prior to VB10.16 treatment start, or the patient has not fully recovered (i.e., Grade \u22641 at baseline) from AEs due to a previously administered treatment.\n5. Has received prior surgery or prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment.\n6. Prior solid organ or tissue transplantation (except corneal transplant).\n7. Prior autologous or allogeneic hematopoietic stem cell transplantation.\n8. Prior chimeric antigen receptor T-cell (CAR-T) therapy.\n9. Prior therapy with a monoclonal antibody, bispecific antibody, or antibody fragment (or other molecule with similar mechanism of action) that engages with stimulatory or co-inhibitory molecules on T cells (e.g., CD3, CTLA-4, PD-1, 4-1BB/CD137), except pembrolizumab in the metastatic setting.\n10. Prior therapy with CPI in the locally advanced setting.\n11. Prior administration with tisotumab vedotin.\n12. Administration of a live (attenuated replicating organism) or non-live (pathogen component or killed whole organism) vaccine, or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine within 30 days prior to VB10.16 treatment start.\n13. Prior administration with a therapeutic HPV16 vaccine.\n14. Prior severe hypersensitivity (\u2265 grade 3) to atezolizumab and/or any of its excipients.\n15. Prior persistent toxicities (\u2265 grade 3) related to pembrolizumab administration.\n16. Participants receiving systemic immunosuppression with immunosuppressive agents such as cyclosporine, azathioprine, methotrexate, or tumor necrosis factor alpha blockers for any concurrent condition.\n17. Chronic administration of systemic corticosteroids: prednisone \\>10 mg daily (or dose equivalent) or an average cumulative dose of \\>140 mg prednisone (or dose equivalent) within the last 14 consecutive days prior to VB10.16 treatment start.\n18. Any planned major surgery.\n\n    Prior or concurrent morbidity:\n\n    Malignancy:\n19. Past or current malignancy other than inclusion diagnosis, except for:\n\n    1. Noninvasive basal cell or squamous cell skin carcinoma.\n    2. Noninvasive, superficial bladder cancer.\n    3. Ductal carcinoma in situ.\n    4. Any curable cancer with a complete response of \\>2 years' duration.",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trial Scientist",
                    "role": "CONTACT",
                    "phone": "+45 31440673",
                    "email": "jkbuchbjerg@nykode.com"
                },
                {
                    "name": "Senior Clinical Trial Manager",
                    "role": "CONTACT",
                    "phone": "+47 90997595",
                    "email": "hwold@nykode.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Ritu Salani, MD MBA",
                    "affiliation": "UCLA Division of Gynecologic Oncology",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mitchell Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Mobile",
                    "state": "Alabama",
                    "zip": "36604",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jennifer Pierce, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.69436,
                        "lon": -88.04305
                    }
                },
                {
                    "facility": "University of California (UCLA) - WHCRU",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90024",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ritu Salani, MD, MBA",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Hoag Memorial Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Newport Beach",
                    "state": "California",
                    "zip": "92663",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Tiffany Beck, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.61891,
                        "lon": -117.92895
                    }
                },
                {
                    "facility": "University of Colorado Cancer Center",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jill Alldrige, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "AdventHealth",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32804",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Robert Holloway, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Parkview Research Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Fort Wayne",
                    "state": "Indiana",
                    "zip": "46805",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Iwona Podzielinski, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.1306,
                        "lon": -85.12886
                    }
                },
                {
                    "facility": "Indiana University",
                    "status": "RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sharon Robertson, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                },
                {
                    "facility": "University of Iowa",
                    "status": "RECRUITING",
                    "city": "Iowa City",
                    "state": "Iowa",
                    "zip": "52242",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "David Bender, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.66113,
                        "lon": -91.53017
                    }
                },
                {
                    "facility": "St. Elisabeth Healthcare",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Edgewood",
                    "state": "Kentucky",
                    "zip": "41017",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Robert Neff, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.01867,
                        "lon": -84.58189
                    }
                },
                {
                    "facility": "University of Kentucky",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Lexington",
                    "state": "Kentucky",
                    "zip": "40511",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Rachel Miller, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.98869,
                        "lon": -84.47772
                    }
                },
                {
                    "facility": "LSU Health Science Center, University Medical Center",
                    "status": "RECRUITING",
                    "city": "New Orleans",
                    "state": "Louisiana",
                    "zip": "70112",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Tara Castellano, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.95465,
                        "lon": -90.07507
                    }
                },
                {
                    "facility": "Atrium Health Levine Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Charlotte",
                    "state": "North Carolina",
                    "zip": "28402",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Erin Crane, MD, MPH",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.22709,
                        "lon": -80.84313
                    }
                },
                {
                    "facility": "Cleveland Clinic",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Peter G Rose, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002583",
                    "term": "Uterine Cervical Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000014594",
                    "term": "Uterine Neoplasms"
                },
                {
                    "id": "D000005833",
                    "term": "Genital Neoplasms, Female"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000002577",
                    "term": "Uterine Cervical Diseases"
                },
                {
                    "id": "D000014591",
                    "term": "Uterine Diseases"
                },
                {
                    "id": "D000005831",
                    "term": "Genital Diseases, Female"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M5830",
                    "name": "Uterine Cervical Neoplasms",
                    "asFound": "Cervical Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17342",
                    "name": "Uterine Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8945",
                    "name": "Genital Neoplasms, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5825",
                    "name": "Uterine Cervical Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17339",
                    "name": "Uterine Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8943",
                    "name": "Genital Diseases, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000594389",
                    "term": "Atezolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "relevance": "LOW"
                },
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M246",
                    "name": "Bevacizumab",
                    "relevance": "LOW"
                },
                {
                    "id": "M349417",
                    "name": "Atezolizumab",
                    "asFound": "Status",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                }
            ]
        }
    },
    "hasResults": false
}